<DOC>
	<DOC>NCT00844376</DOC>
	<brief_summary>The purpose of this study is to estimate the relative bioavailability of the commercial tablet with one prototype extemporaneous preparation suspension formulation, to assist with internal decision making on formulation development.</brief_summary>
	<brief_title>Bioavailability Study for New Atorvastatin Formulation</brief_title>
	<detailed_description>Estimation of Relative Bioavailability</detailed_description>
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<criteria>Healthy male and/or female subjects Body Mass Index (BMI) of approximately 18 to 30 kg/m2 Any condition possibly affecting drug absorption A positive urine drug screening</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>July 2009</verification_date>
	<keyword>Cardiovascular Diseases</keyword>
</DOC>